This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
protein
product name :
Human WDR74 (aa 174-255) Control Fragment Recombinant Protein
catalog :
RP-102831
quantity :
100 uL
price :
US 259.00
product information
Product Type :
Protein
Product Name :
Human WDR74 (aa 174-255) Control Fragment Recombinant Protein
Catalog # :
RP-102831
Quantity :
100 uL
Price :
US 259.00
Clonality :
Recombinant
Purity :
purified
Reactivity :
Human
Applications :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Species :
Human
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
The yeast nucleolar protein NOP7 is necessary for the maturation of 66S preribosomes and interacts with numerous other proteins. One such protein is an essential, conserved WD repeat protein, NOP seven-associated protein 1 (NSA1), that is also required for the yeast 66S ribosome assembly. NSA1 is also associated with the AAA ATPase Rix7, and release of NSA1 from a novel late nucleolar pre-60S requires the Rix7 function. NSA1 has also been found upregulated in mammalian cancer cells, suggesting it may also play a role in cell proliferation.
Format :
Liquid
Applications w/Dilutions :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Aliases :
5730436H21Rik; AA407588; NOP seven-associated protein 1; NSA1; WD repeat domain 74; WD repeat-containing protein 74; Wdr74
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments